DOD Biotech (Thailand) Performance
| DOD Stock | 2.10 0.12 5.41% |
DOD Biotech holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.14, which means a somewhat significant risk relative to the market. DOD Biotech returns are very sensitive to returns on the market. As the market goes up or down, DOD Biotech is expected to follow. Use DOD Biotech mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to analyze future returns on DOD Biotech.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in DOD Biotech Public are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting fundamental indicators, DOD Biotech disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 143 M | |
| Total Cashflows From Investing Activities | -71.7 M |
DOD |
DOD Biotech Relative Risk vs. Return Landscape
If you would invest 198.00 in DOD Biotech Public on August 30, 2024 and sell it today you would earn a total of 12.00 from holding DOD Biotech Public or generate 6.06% return on investment over 90 days. DOD Biotech Public is generating 14.6919% of daily returns assuming 127.8892% volatility of returns over the 90 days investment horizon. Simply put, majority of traded equity instruments are less risky than DOD on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
DOD Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DOD Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DOD Biotech Public, and traders can use it to determine the average amount a DOD Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1149
| Best Portfolio | Best Equity | DOD | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 127.89 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.11 actual daily | 9 91% of assets perform better |
Based on monthly moving average DOD Biotech is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DOD Biotech by adding it to a well-diversified portfolio.
DOD Biotech Fundamentals Growth
DOD Stock prices reflect investors' perceptions of the future prospects and financial health of DOD Biotech, and DOD Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DOD Stock performance.
| Return On Equity | 0.04 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.10 % | |||
| Current Valuation | 2.04 B | |||
| Shares Outstanding | 410 M | |||
| Price To Book | 1.47 X | |||
| Price To Sales | 2.55 X | |||
| Revenue | 1.02 B | |||
| EBITDA | 338.82 M | |||
| Total Debt | 19.31 M | |||
| Book Value Per Share | 3.03 X | |||
| Cash Flow From Operations | 145 M | |||
| Earnings Per Share | 0.12 X | |||
| Total Asset | 1.63 B | |||
About DOD Biotech Performance
By examining DOD Biotech's fundamental ratios, stakeholders can obtain critical insights into DOD Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that DOD Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Things to note about DOD Biotech Public performance evaluation
Checking the ongoing alerts about DOD Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DOD Biotech Public help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DOD Biotech Public is way too risky over 90 days horizon | |
| DOD Biotech Public appears to be risky and price may revert if volatility continues | |
| About 48.0% of the company shares are held by company insiders |
- Analyzing DOD Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DOD Biotech's stock is overvalued or undervalued compared to its peers.
- Examining DOD Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DOD Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DOD Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DOD Biotech's stock. These opinions can provide insight into DOD Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in DOD Stock
DOD Biotech financial ratios help investors to determine whether DOD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOD with respect to the benefits of owning DOD Biotech security.